Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.
Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.
Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in north ...
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.
The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
Factors associated with higher odds of antiviral receipt include clinical influenza testing and ICU admission.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback